FDA approves new pancreatic cancer pill that doubles survival in trial
The FDA has approved daraxonrasib, a twice-daily pill for metastatic pancreatic cancer patients who have already undergone chemotherapy. In a phase 3 trial, the drug extended median overall survival to 13.2 months compared with 6.6 months for chemotherapy. The approval marks a significant advance for a cancer with a five-year survival rate of about 13 percent.
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “U.S. approves breakthrough pancreatic cancer drug, heralding a new era for an intractable disease.” Browse more stories.